Skip to content
value.today

GENEOS Therapeutics, Inc.

Formerly Aeneos Therapeutics, Inc.

Total raised
$37 M
4 rounds on record
Latest round
$5 M
Mar 2023
First round on record
Feb 2019
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of GENEOS Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2023$5 MNo. 4$2 to $10 million

GENEOS Therapeutics, Inc.: Raise no. 4, Mar 2023

Investors in this round

1 investor had bought by the notice of Apr 13, 2023: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $10 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Niranjan Y. Sardesai · Executive Officer, Director
  • Casey Y. Cunningham · Director
  • James Y. Eadie · Director
  • Laurent Y. Humeau · Director
  • Samuel Y. Broder · Director
  • Sangwoo Y. Lee · Director
  • Ted Y. Fjallman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Niranjan Y. Sardesai, Chief Executive Officer. Newest notice filed Apr 13, 2023. Read the notice at the SEC.

equitySEC
Mar 2022$17 MNo. 3$10 to $50 million

GENEOS Therapeutics, Inc.: Raise no. 3, Mar 2022

Investors in this round

9 investors had bought by the notice of Mar 28, 2022: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$17 M of $25 M offered; $8 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Niranjan Sardesai · Executive Officer, Director
  • Casey Cunningham · Director
  • Eadie James · Director
  • Joseph Kim · Director
  • Samuel Broder · Director
  • Sangwoo Lee · Director
  • Ted Fjallman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Niranjan Y. Sardesai, Chief Executive Officer. Newest notice filed Mar 28, 2022. Read the notice at the SEC.

equitySEC
Nov 2020$10 MNo. 2$10 to $50 million

GENEOS Therapeutics, Inc.: Raise no. 2, Nov 2020

Investors in this round

4 investors had bought by the notice of Nov 17, 2020: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $12 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Niranjan Y. Sardesai · Executive Officer, Director
  • Casey Joseph Cunningham · Director
  • J. Joseph Kim · Director
  • James Y. Eadie · Director
  • Samuel Joseph Broder · Director
  • Sangwoo Joseph Lee · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Niranjan Y. Sardesai, President and Chief Executive Officer. Newest notice filed Nov 17, 2020. Read the notice at the SEC.

equitySEC
Feb 2019$5 MNo. 1$2 to $10 million

GENEOS Therapeutics, Inc.: Raise no. 1, Feb 2019

Investors in this round

3 investors had bought by the notice of Feb 27, 2019: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $11 M offered; $6 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, other: Warrants to purchase Common Stock will be issued to M.M. Dillon & Co. and designees of Brookline Capital Markets in addition to any fees paid for commissions and financial advice.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
$50,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Niranjan Y. Sardesai · Executive Officer, Director
  • Casey Y. Cunningham · Director
  • J. Joseph Kim · Director
  • James Y. Eadie · Director
  • Samuel Y. Dr. Broder · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Angela C. Dong (CRD 4367592) · broker-dealer CIM Securities, LLC (Brookline Capital Markets) (CRD 120852) · New York, New YorkSold in CT, NY
  • John Dexter Pearson (CRD 6093501) · broker-dealer CIM Securities, LLC (Brookline Capital Markets) (CRD 120852) · New York, New YorkSold in CT, NY
  • Scott A. Katzmann (CRD 1087840) · broker-dealer CIM Securities, LLC (Brookline Capital Markets) (CRD 120852) · New York, New YorkSold in CT, NY
  • Harris R.L. Lydon Jr. (CRD 1796845) · broker-dealer CIM Securities, LLC (Brookline Capital Markets) (CRD 120852) · New York, New YorkSold in CT, NY
  • Graham A Powis (CRD 2420999) · broker-dealer CIM Securities, LLC (Brookline Capital Markets) (CRD 120852) · New York, New YorkSold in CT, NY
  • Samuel P. Wertheimer (CRD 5984076) · broker-dealer CIM Securities, LLC (Brookline Capital Markets) (CRD 120852) · New York, New YorkSold in CT, NY
  • M.M.Dillon & Co., LLC (CRD 19878) · broker-dealer M.M. Dillon & Co., LLC (CRD 19878) · Greenwich, ConnecticutSold in CT, NY
  • William B. Buchanan, Jr. (CRD 1048722) · broker-dealer CIM Securities, LLC (Brookline Capital Markets) (CRD 120852) · New York, New YorkSold in CT, NY
  • Andrew D. Daniels (CRD 2251612) · broker-dealer CIM Securities, LLC (Brookline Capital Markets) (CRD 120852) · New York, New YorkSold in CT, NY

Remarks in the notice

  • On fees: “In addition to $50,000, Brookline Capital Markets or its designees will be given Warrants to purchase common stock.”

Signed by Niranjan Y. Sardesai, President and Chief Executive Officer. Newest notice filed Feb 27, 2019. Read the notice at the SEC.

equity, optionsSEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • GENEOS Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2023).

    SEC Form D · Apr 2023

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Apr 2023

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of GENEOS Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by GENEOS Therapeutics, Inc.
NameRoleNamed in
Niranjan Y. SardesaiExecutive officerApr 2023
Niranjan SardesaiExecutive officerMar 2022
Casey Y. CunninghamDirectorApr 2023
James Y. EadieDirectorApr 2023
Laurent Y. HumeauDirectorApr 2023
Niranjan Y. SardesaiDirectorApr 2023
Samuel Y. BroderDirectorApr 2023
Sangwoo Y. LeeDirectorApr 2023
Ted Y. FjallmanDirectorApr 2023
Casey CunninghamDirectorMar 2022
Eadie JamesDirectorMar 2022
Joseph KimDirectorMar 2022
Niranjan SardesaiDirectorMar 2022
Samuel BroderDirectorMar 2022
Sangwoo LeeDirectorMar 2022
Ted FjallmanDirectorMar 2022
Casey Joseph CunninghamDirectorNov 2020
J. Joseph KimDirectorNov 2020
Samuel Joseph BroderDirectorNov 2020
Sangwoo Joseph LeeDirectorNov 2020
Samuel Y. Dr. BroderDirectorFeb 2019